Wikipedia

User:Mr. Ibrahem/Eribulin

< User:Mr. Ibrahem
Mr. Ibrahem/Eribulin
Clinical data
Trade namesHalaven
Other namesE7389, ER-086526, NSC-707389, eribulin mesilate (JAN JP), eribulin mesylate (USAN US)
AHFS/Drugs.comMonograph
MedlinePlusa611007
License data
Pregnancy
category
Routes of
administration		Intravenous
Drug classMicrotubule inhibitor[2]
Legal status
Legal status
Identifiers
  • 2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy- 26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy- 7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6) pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one
Chemical and physical data
FormulaC40H59NO11
Molar mass729.908 g·mol−1
3D model (JSmol)
  • CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O
  • InChI=1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1 checkY
  • Key:UFNVPOGXISZXJD-JBQZKEIOSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Eribulin, sold under the brand name Halaven, is a medication used to treat breast cancer and liposarcoma.[3][7] It is used when other treatments have failed.[7] It is given by injection into a vein.[3]

Common side effects include tiredness, hair loss, peripheral nerve damage, abdominal pain, fever, low white blood cells, and low red blood cells.[3] Other side effects may include low potassium, low calcium, and QT prolongation.[3] Use in pregnancy may harm the baby.[3] It is a microtubule inhibitor.[2]

Eribulin was approved for medical use in the United States in 2010 and Europe in 2011.[2][7] In the United Kingdom 0.88 mg cost the NHS about £360 as of 2021.[8] This amount in the United States costs about 580 USD.[9]

References edit

  1. ^ "Eribulin (Halaven) Use During Pregnancy". Drugs.com. 22 October 2019. Archived from the original on 11 July 2020. Retrieved 9 July 2020.
  2. ^ a b c "EriBULin Monograph for Professionals". Drugs.com. Archived from the original on 28 January 2021. Retrieved 15 December 2021.
  3. ^ a b c d e f g h "Halaven- eribulin mesylate injection". DailyMed. 22 December 2017. Archived from the original on 9 July 2020. Retrieved 9 July 2020.
  4. ^ "Eribulin EPAR". European Medicines Agency (EMA). Archived from the original on 9 July 2020. Retrieved 9 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ^ "Eisai Announces Japan Launch Of Anticancer Agent Halaven" (Press release). Eisai Co., Ltd. 19 July 2011. Archived from the original on 4 June 2021. Retrieved 15 February 2021.
  6. ^ "Anticancer Agent Halaven Approved For Treatment Of Locally Advanced Or Metastatic Breast Cancer In China" (Press release). Eisai Co., Ltd. 17 July 2019. Archived from the original on 4 June 2021. Retrieved 15 February 2021.
  7. ^ a b c "Halaven". Archived from the original on 9 July 2020. Retrieved 16 December 2021.
  8. ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 977. ISBN 978-0857114105.
  9. ^ "Halaven Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 11 April 2021. Retrieved 16 December 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Eribulin&oldid=1208650978"